2nd-generation TKI (dasatinib OR nilotinib OR bosutinib by comorbidity matrix) — CML chronic phase 1L for high-risk / younger seeking TFR

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-DASATINIB` `DRUG-NILOTINIB` `DRUG-BOSUTINIB`

ID	`REG-2GEN-TKI-CML`
Type	Regimen
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ELN-CML-2020` `SRC-ESMO-CML-2017` `SRC-NCCN-MPN-2025`

Notes

This regimen entry intentionally bundles dasatinib / nilotinib / bosutinib as one Indication-mapped option. Selection per ELN 2020 comorbidity matrix (see notes in DRUG entries). Faster early molecular response vs imatinib (DASISION, ENESTnd, BFORE trials) but no consistent OS benefit — choice driven by treatment goal (TFR ambition) + comorbidity. Asciminib (STAMP) and ponatinib reserved for resistance / T315I. STUB — requires clinical co-lead signoff before publication.

Used By

Indication

IND-CML-1L-2GEN-TKI - IND-CML-1L-2GEN-TKI